James CH Yang paper

1. Osimertinib+Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth
Factor Receptor Mutated MET-Amplified Non-Small Cell Lung Cancer: TATTON.Hartmaier RJ,
Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC,
Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DA, Kurian N, Cantarini M, Janne PA.
Cancer Discov. 2023 Jan 9;13(1):98-113
2. Yang JC, Ohe Y, Chiu CH, Ou X, Cantarini M, Jänne PA, Hartmaier RJ, Ahn MJ. Osimertinib plus
selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase
1b, open-label, multicenter trial (TATTON Part B). Clin Cancer Res. 2022 May
26:clincanres.4329.2022-1-26 08:36:37.517.
3. Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC,
Shepherd FA, Bulusu KC, Laus G, Collins B, Barrett JC, Hartmaier RJ, Papadimitrakopoulou
V..Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated
advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023 Feb 27;14(1):1071
4. Yang JC, Su WC, Chiu CH, Shiah HS, Lee KY, Hsia TC, Uno M, Crawford N, Terakawa H, Chen
WC, Takayama G, Hsu C, Hong Y, Saintilien C, McGill J, Chang GC. Evaluation of combination
treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable
EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
Invest New Drugs. 2023 Mar 9. doi: 10.1007/s10637-023-01341-y. Online ahead of print.
5. Yang JC, Zhou C, Jänne PA, Ramalingam SS, Kim TM, Riely GJ, Spira AI, Piotrowska Z, Mekhail
T, Garcia Campelo MR, Felip E, Bazhenova L, Jin S, Kaur M, Diderichsen PM, Gupta N, Bunn V,
Lin J, N Churchill E, Mehta M, Nguyen D. Expert Rev Anticancer Ther. 2023 Jan;23(1):95-106
6. Mitsudomi T, Tan D, Yang JC, Ahn MJ, Batra U, Cho BC, Cornelio G, Lim T, Mok T, Prabhash K,
Reungwetwattana T, Ren SX, Singh N, Toyooka S, Wu YL, Yang PC, Yatabe Y. Expert Consensus
Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. J Thorac
Oncol. 2022 Nov 12:S1556-0864(22)01905-0. doi: 10.1016/j.jtho.2022.10.021. Online ahead of
print.
7. Lin EP, Hsu CY, Chiou JF, Berry L, Horn L, Bunn P, Yang JC, Yang PC, Adjei AA, Shyr Y. Cox
Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-
TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune
Checkpoint Inhibitor Survival Benefit. J Thorac Oncol. 2022 Dec;17(12):1365-1374.
8. Wang M*, Yang JC*, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su
WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova
L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Janne PA. Sunvozertinib, a selective EGFR inhibitor
for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer
Discov. 2022 Jul 6;12(7):1676-1689. (co-first author)
9. Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de
Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G,
Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S,
Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y,
Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR
mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33(5):466-487
10. Tan DSW, Kim SW, Ponce Aix S, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip
E, Wolf J, Grohé C, Leighl NB, Riely G, Cui X, Zou M, Ghebremariam S, O'Sullivan-Djentuh L,
Belli R, Giovannini M, Kim DW. Nazartinib for treatment- naive EGFR-mutant non-small cell lung
cancer: Results of a phase 2, single-arm, open-label study. Eur J Cancer. 2022 Sep;172:276-286.
11. Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang
JC, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-
selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a
randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781-792. doi:
10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.

12. Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J,
Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM,
Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K,
Schumacher KM, Bruns R, Otto G, Paik PK. Efficacy and Safety in Patients with MET Exon 14
Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for
Clinical Practice. Clin Cancer Res. 2022 Mar 15;28(6):1117-1126.
13. Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang
Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N,
Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y,
Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW, Yang JC. Efficacy of Aumolertinib (HS-10296) in
Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products
Administration Approval Results From the APOLLO Registrational Trial. J Thorac Oncol. 2022
Mar;17(3):411-422.
14. Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia
Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA.
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon
20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label
Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761.
15. Janne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold
KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L,
Sternberg D, Yu C, Yu HA. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR
Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer Cancer Discov. 2021 Sep 21:
16. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia
Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin
HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Brigatinib versus Crizotinib in Anaplastic
Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer:
Final Results of the Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021 Aug 30:S1556-0864(21)02398-
4. Online ahead of print
17. Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee
CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang
JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-
Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab
in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum
Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct
20;39(30):3391-3402. 
18. Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JCH, Ishii H, Garassino M, de Marinis
F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Xiong
H, Bajars M, Ruisi M, Barlesi F. Avelumab Versus Docetaxel in Patients With Platinum-Treated
Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac
Oncol. 2021 Aug;16(8):1369-1378.
19. Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, Yen SH, Wu YH, Yang JC, Liao
BC, Hsia TC, Chen YM. Lung Cancer in Republic of China. J Thorac Oncol. 2021 Apr;16(4):519-
527.
20. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H,
Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and
Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-
mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 Feb 15;27(4):992-1002.
21. Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang
JC*. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance
in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2021 Jan 13;13(2):272.
(*Corresponding Author)

22. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins
RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi
B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and
Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous
NSCLC. J Thorac Oncol. 2021 Jan;16(1):162-168.
23. Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. Circulating Exosomal Integrin β3 Is
Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial
Irradiation for Brain Metastases: A Prospective Observational Study. Cancers (Basel). 2021 Jan
20;13(3):380.
24. Yang JC*, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y,
Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam
A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With
EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020
Dec;15(12):1907-1918. (*Corresponding author)
25. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen
YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC;
INSIGHT Investigators. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung
cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR
inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir
Med. 2020 Nov;8(11):1132-1143.
26. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A,
García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M,
Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced
ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the
Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592-3603.
27. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart
H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L,
Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken
AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med.
2020 Sep 3;383:931-943.
28. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-
Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian
GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators. Pembrolizumab or
Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung
Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 Jul
20;38(21):2369-2379.
29. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert
M, Pan C, Tan EY, Ko J, Moody SE, Kim DW.Safety and efficacy of nazartinib (EGF816) in adults
with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet
Respir Med. 2020 Jun;8(6):561-572.
30. Yang JC*, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES.Afatinib for the
Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac
Oncol. 2020 May;15(5):803-815. (*Corresponding author)
31. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS,
Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ. TATTON: a multi-arm,
phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant
lung cancer. Ann Oncol. 2020 Apr;31(4):507-516.

32. Hung PS, Huang MH, Kuo YY, Yang JC* The Inhibition of Wnt Restrain KRAS(G12V)-Driven
Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 31;12(4):837.
(*Corresponding author)
33. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D,
Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-
cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a
multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386.
34. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW,
Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell
Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 Feb
20;38(6):538-547.
35. Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan
DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn
YC, Kim TY, Ahn HK, Peters S, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical
Practice Guidelines for the management of patients with locally-advanced unresectable non-small-
cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and
TOS. Ann Oncol. 2020 Feb;31(2):191-201.
36. Yang JC*, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR,
Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. A Randomized Phase 2 Study of Gefitinib
With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer
With EGFR Mutation: Final Overall Survival and Biomarker Analysis. J Thorac Oncol. 2020
Jan;15(1):91-100. (*Corresponding author)
37. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JCH * . Exon 16-
Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive
Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 Jan;15(1):50-61. (*Corresponding author)
38. Yang JC*, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG,
Laus G, Collins B, Pisetzky F, Horn L. Osimertinib Plus Durvalumab versus Osimertinib
Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL
Brief Report. Journal of Thoracic Oncology. 2019 May;14(5):933-936. (*Corresponding author)
39. Yang JC*. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet
Oncol. 2019 May;20(5):602-603. (letter) (*Corresponding author)
40. Yang JC*, Shirish M. Gadgeel SM, Sequist L, Wu SL, Papadimitrakopoulou VA, Su WC, Fiore
J, Saraf S, Raftopoulos , Amita Patnaik A. Pembrolizumab in Combination With Erlotinib or
Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of
Thoracic Oncology 2019 Mar;14(3):553-559. (*Corresponding author)
41. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip
E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of
Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR)
Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung
Cancer. J Clin Oncol. 2018 Nov 1;36(31):3101-3109.
42. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC,
Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A,
Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D and
Popat S. Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. New Engl J
Med. 2018 Nov 22;379(21):2027-2039.
43. Gebski V, Yang JC, Lee CK. Estimating and Interpreting the Overall Survival Benefit of
Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncol. 2018 Aug 1;4(8):1138-1139.
44. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi
T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II

Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung
Cancer. J Clin Oncol. 2018 May 10;36(14):1405-1411.
45. Wu TH, Yang JC*. Real-World or Controlled Clinical Trial Data in Real-World Practice. J
Thorac Oncol. 2018 Apr;13(4):470-472. (editorial) (*Corresponding author)
46. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H,
Rukazenkov YE, Ghiorghiu S, Stetson D, Markovets A, Barrett J, Thress KS, and Jänne PA.
Osimertinib as First-Line Treatment for EGFR-Mutation-Positive Advanced Non-Small-Cell Lung
Cancer. Journal of Clinical Oncology. 2018 Mar 20;36(9):841-849.
47. Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito
A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to
osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials.
Ann Oncol. 2018 Mar 1;29(3):687-693.
48. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T. and Yang
JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With
Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and
Meta-analysis. JAMA Oncology. 2018 Feb 1;4(2):210-216.
49. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai
YY, Huang D, Thress KS and Yang JC*. Outcomes in patients with non-small-cell lung cancer and
acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respiratory
Medicine. 2018 Feb;6(2):107-116. (*Corresponding author)
50. Hsu WH, Yang JC*, Mok TS Loong HH. Overview of current systemic management of EGFR-
mutant NSCLC. Annals of Oncology. 2018 Jan 1;29(suppl_1):i3-i9. (review) (*Corresponding
author)
51. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S,
Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib Plus Chemotherapy
Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell
Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker
Analyses. Journal of Clinical Oncology. 2017 Dec 20;35(36):4027-4034.
52. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao
S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang ZF and Yang JC*.
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases
(BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory
Medicine. 2017 Nov;5(11):891-902. (*Corresponding author)
53. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K,
Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, and
Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-
706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced
Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2017 Nov
10;35(32):3662-3670.
54. Nokihara H, Lu S, Mok TS, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC,
Sugawara S, Nishio M, Takahashi T, Goto K, Chang J., Maemondo M, Ichinose, Y, Cheng Y, Lim
WT, Morita S, Tamura T. Randomized controlled trial of S-1 versus docetaxel in patients with non-
small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in
Lung Cancer). Ann Oncol. 2017 Nov 1; 28(11):2698-2706.
55. Yang JC*, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R,
Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B,
Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase
II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J
Thorac Oncol. 2017 Oct;12(10):1552-1560. (*Corresponding author)
56. Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N,
Satouchi M, Barlesi F.A randomized, open-label, multicenter, phase 3 study to compare the efficacy

and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung
cancer. Ann Oncol. 2017 Sep 1; 28(9):2241-2247.
57. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V,
Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van
Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JC, Ou SI, Pall G, Froesch P, Zalcman G,
Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S,
Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon
A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global,
Multicenter RET Registry. Journal of Clinical Oncology. 2017 May 1;35(13):1403-1410.
58. Yang JC*, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH,
Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC,
Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced
Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical
Oncology. 2017 Apr 20;35(12):1288-1296. (*Corresponding author)
59. Yang JC*, Puri T, Orlando M, Cheng Y. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen
et al. Journal of Clinical Oncology. 2017 Feb 20;35(6):694-696. (*Corresponding author)
60. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC* Checkpoint Inhibitors in
Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017
Feb;12(2):403-407. (brief report) (*Corresponding author)
61. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K,
Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, James Yang
JC*. Gefitinib or erlotinib versus chemotherapy for EGFR mutation-positive lung cancer: individual-
patient-data meta-analysis of overall survival. J National Cancer Inst. 2017 Feb 2;109(6).
(*Corresponding author)
62. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim
DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A,
Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to
Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J
Clin Oncol. 2016 Dec;34(34):4079-4085.
63. Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW,
Ahn MJ, Yang JC, Zhang X. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of
EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 Dec 7;8(368).
64. Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J,
O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A,
Massey D, Wind S, Wu YL. Effect of dose adjustment on the safety and efficacy of afatinib for
EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3
and 6 trials. Ann Oncol. 2016 Nov;27(11):2103-2110.
65. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler
RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad
MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and
pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer:
a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016
Nov;17(11):1497-1508.
66. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC,
Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib
(AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 1;34(28):3375-82.
67. Cheng Y, Haruyasu Murakami H, Yang, PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X,
Enatsu S, Puri T, Orlando M, Yang JC*. Randomized, phase 2 trial of gefitinib with and without
pemetrexed as first-line therapy in patients with advanced non-squamous non-small cell lung cancer
with activating epidermal growth factor receptor mutations Journal of Clinical Oncology. 2016 Sep
20;34(27):3258-66. (*Corresponding author)

68. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi
Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M,
Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with
EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label,
randomised controlled trial. Lancet Oncology. 2016 May;17(5):577-89.
69. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz
A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim
DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II
Global Study. J Clin Oncol. 2016 Mar 1;34(7):661-8.
70. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng
JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand
VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-
small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized
LUX-Lung 5 trial. Ann Oncol. 2016 Mar;27(3):417-23.
71. Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D,
Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell
Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain
Metastases. J Thorac Oncol. 2016 Mar;11(3):380-90.
72. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC*. Epidermal
growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer patients with
leptomeningeal carcinomatosis. J Thorac Oncol. 2015 Dec;10(12):1754-61. (*Corresponding
author)
73. Soria JC, Wu YL, Nakagawa K Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagai S,
Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H and Mok TS.
Gefitinib/chemotherapy versus chemotherapy in EGFR mutation-positive NSCLC after progression
on first-line gefitinib: the phase III randomized IMPRESS study. Lancet Oncology. 2015
Aug;16(8):990-8.
74. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH,
Zhou C, Massey D, Zazulina V, Wu YL, Clinical Activity of Afatinib in Advanced NSCLC
Harbouring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Combined Analysis
of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology. 2015 July;16(7): 830–838.
75. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links
M, Gebski V, Gralla RJ, Yang JC*. The impact of specific EGFR mutations and clinical
characteristics on outcomes from EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR
mutant lung cancer – a meta-analysis. Journal of Clinical Oncology. 2015 Jun 10;33(17):1958-65.
(*Corresponding author)
76. Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL,
Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM,
Perng RP, Yang JC. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment
Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations J Thorac
Oncol. 2015 May;10(5):793-9.
77. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam S, Ahn MJ, Kim SW, Su WC,
Horn L, Haggstrom D, EFelip E, Kim JH, Frewer P, Cantarini M, Brown K, Dicknson P, Giorghiu S
and Ranson M. AZD9291 in EGFR TKI resistant nonsmall cell lung cancer. New England Journal
of Medicine. 2015 Apr 30;372:1689-1699.
78. Yang JC*, Wu YL*, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne
K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov
S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V and Sequist LV.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma
(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3
trials Lancet Oncology. 2015 Feb;16(2):141-51. (*Corresponding author)

79. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough
H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib
maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or
metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer.
2014 Sep;50(13):2219-30.
80. Yang JC*, Sequist LV. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10;32(8):863-4.
(*Corresponding author)
81. Yang JC*, Sequist LV. Reply to F. de Marinis et al. J Clin Oncol. 2014 Mar 10;32(8):865.
(*Corresponding author)
82. Yang JC*, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G,
McCormack R, Mok TS. Epidermal growth factor receptor mutation analysis in previously
unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study
(IPASS). Lung Cancer. 2014 Feb;83(2):174-81. (*Corresponding author)
83. Sequist LV, Yang JC*, Yamamoto N, O”Byrne K, Hirsh V, Mok T, Geater SL, Pavlov SO, Tsai
CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V,
Shahidi M and Schuler M. Phase III study of Afatinib or Cisplatin/Pemetrexed in Metastatic Lung
Adenocarcinoma Patients with Epidermal Growth Factor Receptor Mutations. Journal of Clinical
Oncology. 2013 Sep 20;31(27):3327-3334. (*Corresponding author and equal contribution with
first author).
84. Yang JC*, Hirsh V, Schuler M, Yamamoto N, O’Byrne K, Mok T, Zazulina V, Shahidi M,
Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom Control and Quality of Life in LUX-
Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma
Patients With Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology. 2013
Sep 20;31(27):3342-3350. (*Corresponding author)
85. Yang JC. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncology. 2013 Jun;
14 (7) 564-565. (comments)
86. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu DT,
Zaatar A, Sanchez J, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC*. Impact of EGFR
inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
Journal of The National Cancer Institute. 2013 May 1;105(9):595-605. (*Corresponding
author)
87. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin MY, Yang JC*. MEK inhibitors reverse
resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to
gefitinib. Molecular Oncology. 2013 Feb; 7:112-120. (*Corresponding author)
88. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV,
Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung
adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Lancet Oncol. 2012 May;13(5):539-48.
89. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y,
Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC*. Afatinib versus
placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib,
gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised
trial. Lancet Oncol. 2012 May;13(5):528-38. (*Corresponding author)
90. Medema RH, Lin CC, Yang JC*. Polo-like kinase 1 inhibitors and their potential role in
anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011 Oct 15;17(20):6459-66.
(Review) (*Ccorresponding author)
91. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS,
Shi YK, Badruddin RA, Kang JH, Kim SW, Tan SY, Yang JC*. Clinical and Testing Protocols for
the Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations in East Asian Non-Small Cell
Lung Cancer (NSCLC) Patients – A Combined Clinical-Molecular Pathological Approach. J
Thorac Oncol. 2011 Oct; 6(10): 1663-1669. (*Corresponding author)

92. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY,
Nakagawa K, Da-Tong Chu, Saijo N, Duffield E, Rukazenkov Y, Speake G, Jiang H, Armour A, To
KF, Yang JC, Mok T. Biomarker Analyses and Final Overall Survival Results from a Phase III,
Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically
Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J Clin Oncol. 2011
Jul 20;29(21):2866-74.
93. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy and Safety of
Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients
with Advanced Non-small Cell Lung Cancer. Results of an Exploratory Subgroup Analysis of a
Phase III Trial. Journal of Thoracic Oncology. 2010 May;5(5):688-695.
94. Soo R, Mok T, Cho BC, Yang CH, Lim D, Goldstraw P. Anderson BO. First line systemic
treatment of advanced stage non-small cell lung cancer: Consensus statement from Asian Oncology
Summit 2009. Lancet Oncology. 2009 Nov; 10: 1102–10.
95. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B,
Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL,
Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. New Engl J Med. 2009 Sep 3; 361(10):947-57.
96. Yang CH*, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun
CT, Huang CL, Bean J, Pao W and Yang PC. Specific EGFR mutations predict treatment outcome of
stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy. Journal of
Clinical Oncology. 2008 Jun;26(16):2745-2753. (*Corresponding author)

@Other pertinent publications
97. Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a
plain language summary. Yang JC. Future Oncol. 2023 Feb 16. doi: 10.2217/fon-2022-
0842. Online ahead of print.
98. Wu YL, Lu S, Yang JC, Zhou J, Seto T, Ahn MJ, Su WC, Yamamoto N, Kim DW,
Paolini J, Usari T, Iadeluca L, Wilner KD, Goto K. Final Overall Survival, Safety, and
Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With
ROS1-Positive Advanced NSCLC. JTO Clin Res Rep. 2022 Sep 9;3(10):100406.
99. Chang CL, Hsieh MS, Shih JY, Lee YH, Liao WY, Hsu CL, Yang CY, Chen KY, Lee
JH, Ho CC, Tsai TH, Yang JC, Yu CJ. Real-world treatment patterns and outcomes among
patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell
carcinoma. Ther Adv Med Oncol. 2022 Oct 27;14:17588359221133889. doi:
10.1177/17588359221133889. eCollection 2022.
100. Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T, Siva S,
Tsuboi M, Wu YL, Yang JC. Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell
Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives
on Therapeutic Strategies. Target Oncol. 2023 Feb 8. doi: 10.1007/s11523-023-00947-9.
Online ahead of print.
101. Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A,
Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E,
Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib
Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or
Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From

the Phase III ALTA-1L Study. Clin Lung Cancer. 2022 Jul 21:S1525-7304(22)00152-8.
102. Wu YL, Lu S, Yang JC, Zhou J, Seto T, Ahn MJ, Su WC, Yamamoto N, Kim DW,
Paolini J, Usari T, Iadeluca L, Wilner KD, Goto K. Final Overall Survival, Safety, and
Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With
ROS1-Positive Advanced NSCLC. JTO Clin Res Rep. 2022 Sep 9;3(10):100406.
103. Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W,
Chao BH, Drilon A. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo
in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Future Oncol. 2022 Aug
11. doi: 10.2217/fon-2022-0656. Epub ahead of print. PMID: 35950566.
104. Miura S, Jung HA, Lee SY, Lee SH, Lee MK, Lee YC, Hochmair MJ, Yang CT, Märten
A, Yang JC, Popat S. Sequential Afatinib and Osimertinib in Asian Patients with EGFR
Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis
of Two Global Non-Interventional Studies. Onco Targets Ther. 2022 Aug 22;15:873-882.
105. Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, Liam CK, Hsia TC, Lee
CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon BJ, Nguyen TTH,
Kozuki T, Yang JC, Wu YL, Mok TSK, Tan DS, Yatabe Y. Asian Thoracic Oncology
Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC:
Diagnostic and Therapeutic Considerations. Clin Lung Cancer. 2022 Dec;23(8):670-685
106. Bang TJ, Hu J, Patil T, Barón AE, Gao D, Yang JC, Kuo HY, Huang HC, Sachs PB,
Camidge DR. The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase
Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A
Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX).
Clin Lung Cancer. 2022 Aug 7:S1525-7304(22)00172-3.
107. Yang JC, Schuler M, Popat S, Miura S, Park K, Passaro A, De Marinis F, Solca F,
Märten A, Kim ES. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring
Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. Front
Oncol. 2022 Apr 28;12:834704.
108. Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Huang YL, Chang YL, Chang CH, Yang
JC. Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing
different front-line chemotherapy regimens. Cancer Med. 2022 Mar 29. doi:
10.1002/cam4.4711. Online ahead of print.
109. Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JC,
Lee CK. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for
metastatic non-small-cell lung cancer. Future Oncol. 2022 May;18(14):1793-1799. doi:
10.2217/fon-2021-1184. Epub 2022 Feb 14.
110. Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, Yang JC, Shih JY. Prognostic
Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. JTO
Clin Res Rep. 2020 Dec 26;2(2):100140.
111. Liao BC, Yang JC. Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR
Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC. Thorac Oncol. 2021 Sep;16(9):1426-
1428.
112. Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D,
Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK. Real-world insights into patients with
advanced NSCLC and MET alterations. Lung Cancer. 2021 Sep;159:96-106.
113. Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS,

Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang
JC, Garassino MC. Has COVID-19 had a greater impact on female than male oncologists?
Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021
Jun;6(3):100131.
114. Popat S, Liu G, Lu S, Song G, Ma X, Yang JC. Brigatinib vs Alectinib in Crizotinib-Resistant
Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3). Future
Oncol. 2021 Aug. Accepted for publication.
115. Yang JC*, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley W, Blakely C,
Groen HJ, Bazhenova L, Costa EC, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S,
Wakelee H. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-
Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021
Feb; 2:100114. DOI:https://doi.org/10.1016/j.jtocrr.2020.100114 (*Corresponding Author)
116. Yang JC*, Mok TSK, Lu S, Nakagawa N, Yamamoto N, Shi Y, Zhang L, Soo RA, Morita S,
Tamura T. Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced
NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the
EAST-LC Trial. JTO Clin Res Rep. 2021 Jan;2(3), 100142. (*Corresponding author)
117. Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, Yang JC*, Shih JY. Prognostic
Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras
Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. JTO Clin Res Rep.
2020 Dec;2:100140. (*Corresponding author)
118. Garon EB, Yang JC*, Dubinett SM. The Role of Interleukin 1β in the Pathogenesis of Lung
Cancer. JTO Clin Res Rep. 2020 Feb;1:100001. (*Corresponding author)
119. Kim ES, Melosky B, Park K, Yamamoto N, Yang JC. EGFR tyrosine kinase inhibitors for EGFR
mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol. 2021
Jun;17(18):2395-2408.
120. Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS,
Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang JC,
Garassino MC. Has COVID-19 had a greater impact on female than male oncologists? Results of the
ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 Jun;6(3):100131.
121. Kim ES, Melosky B, Park K, Yamamoto N, Yang JC. EGFR tyrosine kinase inhibitors for EGFR
mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol. 2021
Jun;17(18):2395-2408.
122. Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi
F. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs
docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung
200 trial. Lung Cancer. 2021 Apr;154:92-98.
123. Kok PS, Lee K, Lord S, Yang JC, Rosell R, Goto K, John T, Wu YL, Mok TSK, Lee CK.
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer:
A meta-analysis. Lung Cancer. 2021 Apr;154:113-117.
124. Griesing S, Liao BC, Yang JC*. CD73 Is Regulated by the EGFR-ERK Signaling Pathway in
Non-small Cell Lung Cancer. Anticancer Res. 2021 Mar;41(3):1231-1242. (*Corresponding
Author)
125. Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: lessons
from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2021 Mar;17(8):965-977.
126. Liao BC, Hsu WH, Lee JH, Yang CY, Tsai TH, Liao WY, Ho CC, Lin CC, Shih JY, Yu CJ, Soo
RA, Yang JC*. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic
Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive
NSCLC. JTO Clin Res Rep. 2020 Sep;2:100099. (*Corresponding author)
127. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Märten
A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-

cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020 Dec;16(34):2799-2808.
128. Chen YM, Yang JCH, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu
SY, Hung JY, Wang CC, Yang TY, Yu CJ. Nivolumab safety and efficacy in advanced, platinum-
resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in
Taiwan. J Formos Med Assoc. 2020 Dec;119(12):1817-1826.
129. Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: lessons
from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2020 Nov 26. doi:
10.2217/fon-2020-0951.
130. Lin YT, Yang JC, Chu CY. Esomeprazole-induced Stevens-Johnson syndrome in a patient who
underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer. 2020 Oct;148:177-
178.
131. Wu SG, Yu CJ, Yang JC, Shih JY. The effectiveness of afatinib in patients with lung
adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med
Oncol. 2020 Aug 10;12:1758835920946156. doi: 10.1177/1758835920946156. eCollection 2020.
132. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT,
Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association of
Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients
with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Oncologist. 2020 Aug;25(8):702-711.
133. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang
JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG,
Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL.Two first-in-human studies of
xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with
advanced solid tumours. Br J Cancer. 2020 Apr;122(9):1324-1332.
134. Yang WC, Hsu FM, Chen YH, Shih JY, Yu CJ, Lin ZZ, Lu SH, Yang JC, Cheng AL, Kuo
SH.Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent
lung cancer. Clin Transl Radiat Oncol. 2020 Mar 23;22:76-82.
135. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang
JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. Asian
Thoracic Oncology Research Group expert consensus statement on optimal management of stage III
non-small cell lung cancer. J Thorac Oncol. 2020 Mar;15(3):324-343.
136. Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK.
The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review
and meta-analysis. Acta Oncol. 2020 Jan;59(1):96-100.
137. Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.
Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean
Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2020 Jan;52(1):284-291.
138. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC,
Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association between programmed
death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth
factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J
Cancer. 2020 Jan;124:110-122.
139. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM,
Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN,
Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and
NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 Jan;139:22-
27.
140. Yang CY, Yang JC, Yang PC. Precision Management of Advanced Non-Small Cell Lung
Cancer. Annu Rev Med. 2020 Jan 27;71:117-136.
141. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC*.
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung

Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist.
2019 Dec;24(12):e1417-e1425. (*Corresponding author)
142. Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin
EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC.
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.
EMBO Mol Med. 2019 Dec;11(12):e10581.
143. Liao BC, Griesing S, Yang JC*. Second-line treatment of EGFR T790M-negative non-small cell
lung cancer patients. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890286. doi:
10.1177/1758835919890286. eCollection 2019. (Review) (*Corresponding author)
144. Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Hsieh MS, Chang YL, Chao YT, Chang CH, Yang
JC*. Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for
Thymoma and Thymic Carcinoma: A Retrospective Study. Clin Lung Cancer. 2019
Nov;20(6):e609-e618. (*Corresponding author)
145. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F,
Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced
Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving
Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019 Nov
13;10:125-130.
146. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L,
Märten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-
positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol. 2019 Sep;15(25):2905-2914.
147. Wu TH, Hsiue EH, Yang JC*. Opportunities of circulating tumor DNA in lung cancer. Cancer
Treat Rev. 2019 Aug;78:31-41. (*corresponding author)
148. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ.
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase
inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 Aug;117:107-115.
149. Hong ST, Lin H, Wang CS, Chang CH, Lin AM, Yang JC, Lo YL. Improving the anticancer
effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-
responsive and targeting peptides. J Nanobiotechnology. 2019 Aug 19;17(1):89.
150. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ,
Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for
chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019
Jul;15(20):2371-2383.
151. Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH,
Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. First-line afatinib for advanced
EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung
Cancer. 2019 Jul;133:10-19.
152. Liang SK, Ko JC, Yang JC, Shih JY. Afatinib is effective in the treatment of lung
adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019
Jul;133:103-109.
153. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ,
Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for
chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019
Jul;15(20):2371-2383.
154. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S,
Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park
K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7):
impact of afatinib dose adjustment and analysis of mode of initial progression for patients who
continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579.

155. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K,
Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C,
Märten A, Tang W, Yamamoto N. Sequencing of therapy following first-line afatinib in patients with
EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019 Jun;132:126-131.
156. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY,
Yang JC, Yu CJ. Clinical outcomes and secondary epidermal growth factor receptor (EGFR)
T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer
patients with activating EGFR mutations. Int J Cancer. 2019 Jun 1;144(11):2887-2896.
157. Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY,
Chiang DL, Wu HD, Yang JC, Yu CJ. Weaning outcome of solid cancer patients requiring
mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun;118(6):995-1004.
158. Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR
mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med
Oncol. 2019 Apr ;11:1-17. (Review).
159. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam
SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M
mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis
of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901.
160. Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC.
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients
with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 Feb;14(1):57-65.
161. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M,
Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY. Pan-Asian adapted
Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung
cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol.
2019 Feb 1;30(2):171-210.
162. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler
RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad
MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival from KEYNOTE-021
Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for
Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Jan;14(1):124-129.
163. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. Prognostic factors and treatment outcomes of
malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med
Assoc. 2019 Jan;118(1 Pt 2):230-236.
164. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens
M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V.
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell
lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 Nov;125:273-281.
165. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk
M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC. Activity of Afatinib in Heavily
Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global
Named Patient Use Program. J Thorac Oncol. 2018 Dec;13(12):1897-1905.
166. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L,
Golembesky A, Märten A, Cufer T. Sequential treatment with afatinib and osimertinib in patients
with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol.
2018 Nov;14(27):2861-2874.
167. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. Driver mutations of young lung adenocarcinoma
patients with malignant pleural effusion. Genes Chromosomes Cancer. 2018 Oct;57(10):513-521.
168. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M,
Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y,

Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients
with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018
Sep;109(9):2852-2862.
169. Liao BC, Lin CC, Yang JC*. Treating brain metastases in non-small cell lung cancer patients:
what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018
Jun;19(8):851-864. (review) (*Corresponding author)
170. Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios
CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin
Yang J, Paz-Ares L, Park K. Afatinib as First-line Treatment of Older Patients With EGFR
Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-
Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer. 2018 Jul;19(4):e465-e479.
171. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans
AC, Kim HR, Kim JH, Krebs MG, Yang JC, Bui K, Weilert D, Harvey RD. The effect of
itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018
Jun;84(6):1156-1169.
172. Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR,
Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho
BC. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to
ALK Inhibitors. Cancer Res. 2018 Jun 15;78(12):3350-3362.
173. Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R,
Davies L, Gebski V, Gralla R, Mok T, Yang JC. The Value of Early Depth of Response in
Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018
Jun;13(6):792-800.
174. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC*. Best
Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR
Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 May;19(3):e361-
e372. (*Corresponding author)
175. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY,
Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical
Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or
Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018 Apr 19;9(10):1813-1820.
176. Liao BC, Bai YY, Lee JH, Lin CC, Lin SY, Lee YF, Ho CC, Shih JY, Chang YC, Yu CJ, Yang
JC, Yang PC. Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small
cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. J Formos Med Assoc.
2018 Apr;117(4):326-331.
177. Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C. Adjusted Indirect
Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet
Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Clin Drug Investig. 2018 Apr;38(4):319-331.
178. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N,
O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC*. Does EGFR
Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-
Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing
Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). The Patient 2018 Feb;11(1):131-
141. (*Corresponding author)
179. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang
JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. Epidermal growth factor receptor mutation predicts
favorable outcomes in non-small cell lung cancer patients with brain metastases treated with
stereotactic radiosurgery. Radiotherapy and Oncology. 2018 Feb；126(2):368-374.
180. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F,

Schulz M, Liu S, Gupta R, Kotb A, Ou SI. Cumulative incidence rates for CNS and non-CNS
progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018
Jan;118(1):38-42.
181. Yang JC*, Mok T, Han B, Orlando M, Puri T, Park K. A Review of Regimens Combining
Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment
of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan;19(1):27-
34. (review) (*Corresponding author)
182. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad
V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong
WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor
resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med. 2017 Nov
8;9(415).
183. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J,
Gold KA, Cantarini M, Barrett JC, Jänne PA. Modulation of Biomarker Expression by Osimertinib:
Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017
Oct;12(10):1588-1594.
184. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ.
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced
Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist. 2017
Sep;22(9):1075-1083.
185. Liao BC, Lin CC, Lee JH, Yang JC*. Optimal management of EGFR-mutant non-small cell lung
cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017
Aug;110:7-13. (*Corresponding author)
186. Soo RA, Stone EC, Cummings KM, Jett JR, Field JK, Groen HJ, Mulshine JL, Yatabe Y,
Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee
HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JC, Sequist LV, Shaw
AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin
CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.
Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 Aug;12(8):1183-1209.
187. Wang HT, Lin JH, Yang CH, Haung CH, Weng CW, Maan-Yuh Lin A, Lo YL, Chen WS, Tang
MS. Acrolein induces mtDNA damages, mitochondrial fission and mitophagy in human lung cells.
Oncotarget. 2017 Jul 31;8(41):70406-70421.
188. Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne
PA, Mitsudomi T, Goss GD. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation
in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Jul;12(7):1061-
1070.
189. Gandhi L, Ignatius Ou SH, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes
BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A,
Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-
positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J
Cancer. 2017 Jun 21;82:27-33.
190. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY. Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-
Small-cell Lung Cancer. Clin Lung Cancer. 2017 May;18(3):324-332.
191. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. Risk of treatment-
related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib,
erlotinib and afatinib in advanced EGFR-mutated non-small-cell lung cancer. J Thorac Oncol. 2017
Apr;12(4):633-643.
192. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin
TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK,

Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. A systematic review and
meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on
treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017 Apr
13;8(25):41474-41486.
193. Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. Acquired BRAF V600E Mutation as
Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol. 2017 Mar;12(3):567-572.
194. Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hisao CF, Lee JH, Chen CY, Chen CH, Chang
GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS,
Shih WC, Shie SH, Yang TY, Lan Q, Nothman N, Chen CJ, Chanock SJ, Yang PC, Hisung CA.
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients
treated with first-line TKIs. Am J. Respir Crit Care Med. 2017 Mar 1;195(5):663-673.
195. Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B,
Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y,
Fukuoka M. Efficacy according to blind independent central review: Post-hoc analyses from the
phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in
Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017 Feb;104:119-
125.
196. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL,
Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M,
Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N,
Chih-Hsin Yang JC, Zhou C, Vokes E. The Potential of Combined Immunotherapy and
Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017
Feb;12(2):194-207.
197. Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S,
Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K.
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung
cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017 Feb
1;28(2):270-277.
198. Wu YL*, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T,
Yamamoto N, O’Byrne K, Hirsh V, Gibson N, Massey D, Kim M and Yang JC*. EGFR mutation
detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and
6. Br. J Cancer. 2017 Jan 17;116(2):175-185. (*Corresponding author)
199. Liao BC, Lin CC, Yang JC*. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current
Status of Afatinib. Curr Oncol Rep. 2017 Jan;19(1):4. doi: 10.1007/s11912-017-0560-2. PMID:
28138934. (review) (*Corresponding author)
200. Wu TH, Hsiue EH, Lee JH, Lin CC, Yang JC*. New data on clinical decisions in NSCLC
patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 Jan;11(1):51-55. (review)
(*Corresponding author)
201. Hsiue EH, Lee JH, Lin CC, Yang JC*. Profile of the therascreen® EGFR RGQ PCR kit as a
companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016
Dec;16(12):1251-1257. (review) (*Corresponding author)
202. Liao BC, Lin CC, Lee JH, Yang JC*. Update on recent preclinical and clinical studies of T790M
mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed
Sci. 2016 Dec 3;23(1):86. doi: 10.1186/s12929-016-0305-9. PMID: 27912760; PMCID:
PMC5135794. (Review) (*Corresponding author)
203. Lin KH, Hong ST, Wang HT, Lo YL, Lin AM, Yang JC. Enhancing Anticancer Effect of
Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-
Penetrating Peptide or Glutathione and Tween 80. Int J Mol Sci. 2016 Nov 29;17(12):1998. doi:
10.3390/ijms17121998. PMID: 27916828; PMCID: PMC5187798.
204. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M,

Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Preclinical
Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases
Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct
15;22(20):5130-5140.
205. Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F,
Garrus JE, Close S, Park K. A Randomized Phase 2 Study Comparing the Combination of
Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary
Adenocarcinoma. J Thorac Oncol. 2016 Oct;11(10):1736-44.
206. Lu S, Cheng Y, Zhou CC, Wang J, Yang JC, Zhang PH, Zhang XQ, Wang X, Orlando M, Wu
YL. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other
Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced
Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 Sep;17(5):e103-e112.
207. Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic Lymphoma Kinase (ALK) Kinase Domain
Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung
Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 Sep;17(5):e77-e94-60. (review)
208. Lu SL, Hsu FM, Chen KY, Ho CC, Yang JC, Cheng JC. Maximizing Benefits from Maintenance
Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small
Cell Lung Cancer. Case Rep Oncol. 2016 Aug 17;9(2):474-480.
209. Hsiue EH, Lee JH, Lin CC, Yang JC. Safety of gefitinib in non-small cell lung cancer treatment.
Expert Opin Drug Saf. 2016 Jul;15(7):993-1000. (review)
210. Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY. Efficacy of
Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma
Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. J Thorac
Oncol. 2016 Jul;11(7):1140-52.
211. Liang YH, Shao YY, Liao BC, Lee HS, Yang JC, Chen HM, Chiang CJ, Cheng AL, Lai MS.
Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in
Taiwan: Daily Practice. J Cancer. 2016 Jul 7;7(11):1515-23.
212. Chen YL, Lee CT, Lu CC, Yang SC, Chen WL, Lee YC, Yang CH, Peng SL, Su WC, Chow
NH, Ho CL. Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene
Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS One. 2016 Jun
28;11(6):e0158125.
213. Schuler M, Yang JC, Planchard D. Reply to the letter to the editor "What is the clinical impact of
the LUX-Lung 5 trial?" by A. Addeo. Ann Oncol. 2016 Jun;27(6):1172-3.
214. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang
JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in
pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer.
2016 Apr; 94:46-53.
215. Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T,
Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy
versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or
Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a
Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar;11(3):370-9.
216. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. The
mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung
adenocarcinoma patients. Oncotarget. 2016 Mar 15; 7(11): 12404–12413.
217. Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N,
Yang JC. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus
Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic
Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III
Trial. Clin Lung Cancer. 2016 Mar; 17(2):150-60.

218. Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The
Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic
Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015 Dec
31;10(12):e0145936.
219. Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S,
Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy
Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A
Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory
Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment
Regimens. J Thorac Oncol. 2015 Dec;10(12):1745-53.
220. Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung
cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015 Sep;7(5):274-90.
(review)
221. Yang JC, Ahn MJ, Nakagawa K, Tamura T, Barraclough H, Enatsu S, Cheng R, Orlando M.
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer:
Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Res Treat. 2015
Jul;47(3):424-35.
222. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. Clinical and prognostic implications of
RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Lung Cancer. 2015 May;88(2):208-14.
223. Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC and Shih JY. IL-8
Confers Resistance to EGFR Inhibitors by Inducing Stem Cell Properties in Lung Cancer.
Oncotarget. 2015 Apr 30;6(12):10415-31.
224. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang
NJ, Chang JY, Chen LT. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor
patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86.
225. Liao BC, Lin CC, Yang JC*. Second and third-generation epidermal growth factor receptor
tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opin Oncol. 2015 March
;27(2):94-101. (review) (*Corresponding author)
226. Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang
JC*, Lai MS. Comparative effectiveness of first-line platinum-based chemotherapy regimens for
advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar;16(2):137-43.
(*Corresponding author)
227. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AMY*, Yang JC*. Chloroquine
enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLOS one 2015
Mar 25;10(3):e0119135. (* Corresponding author)
228. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, Yang PC. Advanced non-small cell lung
cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient
prognosis. J Geriatr Oncol. 2015 Jan;6(1):38-45.
229. Lu WC, Lin CC, Yang JC. Angiokinase inhibitors in non-small cell lung cancer. Clinical
Investigation. 2015 Jan ;5(1),47-59. (review)
230. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of Renal Cysts
after Crizotinib Treatment in Advanced ALK-Positive Non-Small-Cell Lung Cancer. J Thorac
Oncol. 2014 Nov;9(11):1720-1725.
231. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC,
Laio WY, Yang PC, Yang JC*.Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in
Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Sep;9(9):1385-92.
(*Corresponding author)
232. Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin
M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE.Biomarker Analyses from

a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without
Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer
(ATLAS). J Thorac Oncol. 2014 Sep;9(9):1411-7.
233. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T,
Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-
analysis. Lung Cancer. 2014 Aug;85(2):230-8.
234. Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC,
Yang PC. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1
fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014
Aug;9(8):1171-9.
235. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach
WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-
label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of
intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014
Jun;32(3):445-51.
236. Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H,
Voss F, Taube T, Yang JC*. A phase I study of two dosing schedules of volasertib (BI 6727), an
intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer.
2014 May 13;110(10):2434-40. (*Corresponding author)
237. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R,
Spigel DR, Yang JC, Ciardiello F. Treatment of Advanced Non-Small-Cell Lung Cancer With
Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an
International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung
Cancer. 2014 May;15(3):173-81.
238. Kao HF, Chen IC, Hsu C, Chang SY, Chien SF, Chen YC, Hu FC, Yang JC, Cheng AL, Yeh
KH. Chlorhexidine for the prevention of blood stream infection associated with totally implantable
venous ports in patients with solid cancers. Support Care Cancer. 2014 May;22(5):1189-97.
239. Interview of James Chih-Hsin Yang, Changing advanced lung cancer into chronic disease. Lung
Cancer Management 2014 Feb 5 ;3(1),1-5.
240. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC,
Yang PC, Shih JY. Multi-gene analyses from waste brushing specimens for patients with peripheral
lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec;82(3):420-5.
241. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS.
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma
irrespective of tumor size. PLoS One 2013 Nov 11;8(11):280276.
242. Johnson B, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY,
Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, and Miller V. ATLAS:
Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy
With or Without Erlotinib, After Completion of Chemotherapy With Bevacizumab for First-Line
Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) J Clin Oncol. 2013 Nov
1;31(31):3926-34.
243. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated
insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from
lung adenocarcinomas. J Neurooncol. 2013 Oct;115(1):61-70.
244. Chang GC, Tsai CM, Hsia TC, Yang CH, Abdulnabi R, Blair JM, Linn C. Second-line
pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label
single-arm study. J. Formosan Med Asso. 2013 Sep ;112(9):518-526.
245. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ,
Rukazenkov Y. Tumor response and health-related quality of life in clinically selected patients from
Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses

from the IPASS study. Lung Cancer. 2013 Aug;81(2):280-7.
246. Kao HF, Lin CC, Yang JC*. EGFR inhibitors as the first-line systemic treatment for advanced
non-small-cell lung cancer. Future Oncol. 2013 Jul;9(7):991-1003. (review) (*Corresponding
author)
247. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. Neoadjuvant
Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2013 Jul;14(4):418-24.
248. Yang JC*, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O’Brien D,
Wolf J, Cohen E. Diarrhea associated with afatinib, an oral ErbB family blocker. Expert review of
Anticancer Therapy. 2013 Jun;13(6):729-36. (review) (*Corresponding author)
249. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, Yang PC, Shih JY. Survival of lung
adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2013 Jun;41(6):1409-18.
250. Liao BC, Lin CC, Yang JC*. First-Line Management of Egfr-Mutated Advanced Lung
Adenocarcinoma: Recent Developments. Drugs. 2013 Mar;73(4):357-69. (review)
(*Corresponding author)
251. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M,
Yang JC. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer
patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial
(LUX-Lung 1). J Thorac Oncol. 2013 Feb;8(2):229-37.
252. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih
JY, Lin SB. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor
receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 1;328(1):144-51.
253. Lee YC, Lee LM, Yang CH, Lin AM, Huang YC, Hsu CC, Chen MS, Chi CW, Yin PH, Kuo
CD, Liao JF, Lee HC. Norcantharidin suppresses cell growth and migration with enhanced
anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. Oncol Rep.
2013 Jan;29(1):237-43. 
254. Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC*, Lai MS*. Comparison of gefitinib
and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer.
2013 Jan;49(1):106-14. (*Co-corresponding authors)
255. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC*, Lai MS. Survival Following
Surgery with or without Adjuvant Chemotherapy for Stage I-IIIA Non-Small Cell Lung Cancer: An
East Asian Population-Based Study. Oncologist. 2012 Oct;17(10):1294-302. (*Co-corresponding
authors)
256. Yang JC. Small-Cell Lung Cancer Treatment: Where is the Target? J Thorac Oncol. 2012
Sep;7(9):1327-8. (editorial)
257. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by
gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung
cancer. Lung Cancer. 2012 Aug;77(2):346-52.
258. Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, Ting-Fang Shih T, Yang PC, Yang
JC*. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with
first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012 Aug;36(2):387-
96. (*Corresponding author)
259. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina
E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely
GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung
cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but
lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012 Jul 31;109(31):E2127-
33.
260. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors

impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma
patients in prospective clinical trials of systemic therapy. Oncologist. 2012 Jul ;17(7):970-7.
261. Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC. Clinical Outcomes in
Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clin Cancer Res.
2012 Jun 15;18(12):3470-7.
262. Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC. Advanced non-small cell lung
cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer. 2012
Jun 13;12:241.
263. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. Genetic Polymorphism
of XRCC1 Arg399Gln Is Associated With Survival in Non-Small-Cell Lung Cancer Patients Treated
With Gemcitabine/Platinum. J Thorac Oncol. 2012 Jun;7(6):973-981.
264. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL,
Yang PC. Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts
Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung
Cancer. Journal of Clinical Oncology 2012 Feb 01;30(4):433-40.
265. Tsai TH, Wu SG, Chang YL, Wu CT, Tsai MF, Wei PF, Yang CH, Yu CJ, Yang PC, Shih JY.
Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted
Therapy in Advanced Lung Adenocarcinoma. J Thorac Oncol. 2012 Jun;7(6):993-1000.
266. Chung KP, Huang YT, Chang YL, Yu CJ, Yang CH, Chang YC, Shih JY, Yang PC. Clinical
significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal
growth factor receptor tyrosine kinase inhibitor treatment. Chest. 2012 Feb;141(2):420-8.
267. Girard N, Sima CS, Jackman DM, Sequist LV, Chen HQ, Yang JC, Ji HB, Waltman B, Rosell R,
Taron M, Zakowski MF, Ladanyi M, Riely G and Pao W. Nomogram to predict the presence of
EGFR activating mutation in lung adenocarcinoma. European Respiratory J. 2012
Feb;39(2):366-72.
268. Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC and Lai MS. Survival of
patients with small cell lung cancer in Taiwan. Oncology 2012 Jan 20;82(1):19-24.
269. Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC. EML4-
ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J
Thorac Oncol. 2012 Jan;7(1):98-104.
270. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang CH, Chu DT, Lia M, Chen YM, Kuo HP,
Negoro S, Lam KC, Armour A, Magill R and Fukuoka M. Health-related quality-of-life in a
randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected
patients from Asia with advanced NSCLC. J Thorac Oncol. 2011 Nov;6(11):1872-80.
271. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A
phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage
III non-small cell lung cancer. BMC Cancer. 2011 Oct 7;11:430.
272. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ and Yang PC. Thymidylate
synthase and dihydrofolate reductase expression in nonsmall cell lung cancer carcinoma: the
association with treatment efficacy of pemetrexed. Lung Cancer. 2011 Oct;74(1):132-8.
273. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R,
Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci RA,
Ricker JL, Garson DM, Soo RA. Phase II trial of Linifanib (ABT-869) in patients with advanced
nonsmall cell lung cancer. J Thorac Oncol. 2011Aug;6(8):1418-1425.
274. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY and Yang PC. Effectiveness of tyrosine kinase
inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical
significance in non-small cell lung cancer. Clin Can Res. 2011 Jun 1;17(11):3812-21.
275. Wu JY, Shih JY, Chen KY, Yang CH, Yu CJ, Yang PC. Gefitinib therapy in patients with
advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor
mutations. Medicine. 2011 May;90(3):159-67.

276. Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY and Yang PC. Good response to
pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR)
mutations. Lung Cancer. 2011 Jun;72(3):333-9.
277. Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, Shih JY, Yang PC. Comparison of
gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutation. Lung Cancer. 2011
May;72(2):205-12.
278. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB,
Wu CP, Shih JY, Yang PC. Slug confers resistance to the epidermal growth factor receptor tyrosine
kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr ;183(8):1071-9.
279. Lee LJ, Chung CW, Chang YY, Lee YC, Yang CH, Liou Sh, Liu PH, Wang JD. Comparison of
the quality of life between patients with non-small cell lung cancer and healthy controls. Qual Life
Res. 2011 Apr ;20(3):415-23.
280. Lin ZZ and Yang CH*. Current Roles and Future Perspectives of Epidermal Growth Factor
Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Eur J Clin Med
Oncol. 2011 March online publish. (Non-SCI) (Review) (*Corresponding author)
281. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, DeMarinis F, Abratt RP, Wolf
J, Blackhall FH, Langmuir P, Milenkova T, Read J and Vansteenkiste J Vandetanib plus pemetrexed
for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind
phase III trial (ZEAL). J Clin Oncol. 2011 Mar 10:29(8):1067-74.
282. Lin CC and Yang CH*. Optimal management of patients with nonsmall cell lung cancer and
EGFR mutation. Drug. 2011 Jan ;71(1)79-88. (review) (*Corresponding author)
283. Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L,
Yang CH* and Mok T. Chemotherapy response in East Asian non-small cell lung cancer patients
harboring wild type or activating mutation of epidermal growth factor receptors. Journal of
Thoracic Oncology. 2010 Sep; 5(9): 1424-9. (*Corresponding author)
284. Sequist LV and Yang CH. A randomized phase III trial of BIBW 2992 versus chemotherapy as
first-line treatment for stage IIIB/IV adenocarcinoma of the lung harboring and epidermal growth
factor receptor-activating mutation. Community Oncology. 2010 Jul;7:1-4. (Non-SCI)
285. Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC. Use of cetuximab after failure
of gefitinib in patients with advanced non-small cell lung cancer. Clin Lung Cancer. 2010 Jul
1;11(4):257-63.
286. Shao YY, Lin CC, Yang CH*. Gefitinib or erlotinib in the treatment of advanced non-small cell
lung cancer. Discov Med. 2010 Jun;9(49):538-45. (*Corresponding author)
287. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH*. Characteristics and risk factors of
oxaliplatin-related hypersensitivity reaction. J Formos Med Assoc. 2010 May;109(5):362-8.
(*Corresponding author)
288. Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH*. Pemetrexed for heavily pretreated
patients with advanced non-small cell lung cancer. J Formos Med Assoc. 2010 May ;109(5):338-44.
(*Corresponding author)
289. Wu JY, Yu CJ, ShihJY, Yang CH and Yang PC. Influence of first-line chemotherapy and EGFR
mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer. 2010
Mar;67(3):348-54.
290. Huang CT, Yen RF, Cheng ME, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang
PC. Correlation of F-18-flurodeoxyglucose-positron emission tomography maximal standardization
uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical Oncology. 2010 Mar
;27(1):9-15.
291. Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Octagenarians with advanced non-
small cell lung cancer treatment modalities, survival and prognostic factors. Journal of Thoracic
Oncology. 2010 Jan;5(1):82-9.
292. Cho BC, Kim JH, Soo RA and Yang CH*. The Role of Monoclonal Antibody in Combination
with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer.

Yonsei Med J. 2010 Jan ; 51(1):1-8. (review) (*Corresponding author)
293. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, Yang PC. Second-line treatments after
first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer. 2010
Jan;126(1):247-55.
294. Gainford MC, Yang CH, Liu MY et al. Translation and cultural adaptation of the patient disease
and treatment assessment form. A novel quality of life instrument for use in Taiwan. Asia Pacific
Journal of Clin Oncology. 2009 Sep, 4(3):149-156. (Non-SCI)
295. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, Lin ZZ, Yu CJ, Cheng AL, Yang PC.
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with
gefitinib treatment. Lung Cancer. 2009 Jun;64(3):346-51.
296. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY.
Comparison of epidermal growth factor receptor mutations between primary and corresponding
metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009
Apr;20(4):696-702.
297. Lin MY, Chao PL, Fang SF, Chi CW, Yang CH. Melatonin inhibits arsenite-induced peripheral
neurotoxicity. J Pineal Res. 2009 Jan ;46(1):64-70.
298. Lin CC and Yang CH*. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or
poor performance status patients with advanced non-small cell lung cancer. Target Oncol. 2009
Jan;4(1):37-44. (Review) (*Corresponding author)
299. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH*.
Gemcitabine plus Conventional-dose Epirubicin versus Gemcitabine plus Cisplatin as First-line
Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Carcinoma-A randomized phase II trial.
Lung Cancer. 2008 Dec;62(3),334-343. (*Corresponding author)
300. Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC. Good
Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor
(EGFR) Mutations with the Classical Mutation Pattern. Oncologist. 2008 Dec;13(12):1276-84.
301. Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL and Yang CH*. Acute encephalopathy following
arsenic trioxide for metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original
Investigations. 2008 Nov;26(6):659-61. (*Corresponding author)
302. Perng RP, Yang CH*, Chen YM, Chang GC, Lin gMC, Hsieh RK, Chu NM, Lai RS, Su WC,
Tsa CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang
WC, Kou HP, Yu CT, Lin ZZ Kao WY. High efficacy of erlotinib in Taiwanese NSCLC patients in
an expanded access program study previously treated with chemotherapy. Lung Cancer. 2008
Oct;62(1):78-84. (*Co-corresponding author)
303. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC. Frequent
EGFR mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008
Oct;32(4):924-30.
304. Wu JU, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY,
Yang PC. First or second-line therapy with gefitinib produces equal survival in non small cell lung
cancer. Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53.
305. Wu JY, WuSG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Lung cancer with
epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment
response. Clinical Cancer Research. 2008 Aug 1;14(15):4877-82.
306. Yang CH*. EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer in
East Asia: present and future. Lung Cancer. 2008 Jun ;60:S23-S30 supplement 2. (review)
(*Corresponding author)
307. Lin ZZ, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC and Yang CH*
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly
paclitaxel as first-line treatment. Lung Cancer. 2008 May;60(2):215-21. (*Corresponding author)
308. Chen JP, Lo Y, Yu CJ, Hsu C, Shih JY and Yang CH*. Predictors of toxicity of weekly
Docetaxel in chemotherapy-treated nonsmall cell lung cancers. Lung cancer. 2008 Apr;60(1):92-7.

(*Corresponding author)
309. Chou YH, Chao PL, Tsai MJ, Cheng HH, Chen KB, Yang DM, Yang CH* and Lin MY.
Arsenite-induced cytotoxicity in dorsal root ganglion explants. Free Radical Biol. Med. 2008 April
15;44(8):1553-61. (*Co-corresponding author)
310. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH and Yang PC. Caveolin-1 expression is
significantly associated with drug resistance and poor prognosis in advanced non-small cell lung
cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008 Jan;59(1):105-
10.
311. Gow CH, Chien CR, Chang YL, Chiu YH, Shih JY, Chang YC, Yu CJ, Yang CH and Yang PC.
Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal
Growth Factor Receptor Mutations on Clinical Response. Clinical Cancer Research. 2008 Jan
1;14(1):162-8.
312. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Moti N, Szoke J, Broderick S,
Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Geral W, Huang SF, Yang PC, Miller V,
Ladayi M, Yang CH and W Pao. MET amplification occurs with or without T790M mutations in
EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci.
2007 Dec 26;104(52):20932-7.
313. Lin CC, Yeh KH, Yang CH, Hsu C, Tsai YC, Hsu WL, Cheng AL and Hsu CH.
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients
with metastatic or recurrent esophageal squamous cell carcinoma. Anticancer Drugs. 2007
Jul;18(6):703-8.
314. Lin MY, Chao PL, Fang SF, Chi CW, Yang CH*. Endoplasmic reticulum stress is involved in
arsenite-induced oxidative injury in rat brain. Toxicol. Appl. Pharmacol. 2007 Jul;224:138-146.
(*Corresponding author)
315. Chen YM, Yu CJ, Yang CH, Perng RP, Tsia Cm, Shih JF, Cheng AL, Lefresene F, Barbier M
Pouget JC and Yang PC. A phase II study of oral vinorelbine in combination with cisplatin
conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung
carcinoma. Lung Cancer. 2007 Apr;56(1):89-95.
316. Lin MY, Fang SF, Chao PL, Yang CH*. Melatonin attenuates arsenite-induced apoptosis in rat
brain: Involvement of mitochondrial and ER pathways and aggregation of -synuclein. J. Pineal
Res. 2007 Mar;43:163-71. (*Corresponding author)
317. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH*. Arsenic trioxide in patients with
hepatocellular carcinoma : a phase II trial. Investigational New Drugs. 2007 Feb;25:77-84.
(*Corresponding author)
318. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS and Yang CH*. A
phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with
chemotherapy-pretreated metastatic breast cancer. Anticancer Research. 2007 Jan;27:641-646.
(*Corresponding author)
319. Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, Tsai CM, Yang CH, Chen YM, Yu
CJ, Lee JJ, Hsu HS, Yu CT, Kao EL and Chiu CH. Revisit of 1997 TNM Staging System--Survival
Analysis of 1112 Lung Cancer Patients in Taiwan. Jpn J Clin Oncol. 2007 Jan;37(1):9-15.
320. Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC.
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by
esophagectomy for locally advanced esophageal cancer. Ann Oncology. 2007 Jan;18:93-8.
321. Chang, A, Parikh, P, Thongprasert S, Tan EH, Perng, RP, Ganzon, D, Yang CH, Tsao CJ,
Watkins C, Botwood N and Thatcher, N. Gefitinib (IRESSA) in Patients of Asian Origin with
Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal
of Thoracic Oncology. 2006 Oct;1(8):847-855.
322. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C Chang GC and
Yang PC. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive
advanced non-small cell lung cancer patients. Cancer. 2006 Sep 20;107:1873-82.

323. Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP,
Yang PC, Yang CH*. Predictive factors of gefitinib anti-tumor activity in East Asian advanced non-
small cell lung cancer patients. J Thoracic Oncol. 2006 Jul;1,520-526. (*Corresponding author)
324. Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP and Yang
PC. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response
to gefitinib therapy and survival of patients with advanced non-small cell lung cancer. International
J of Cancer. 2006 Feb;118(4),963-969.
325. Chien CR and Yang CH *. Thoracic radiotherapy for stage IV non-small cell lung cancer.
Radiotherapy and Oncology. 2006;78,110. (*Corresponding author)
326. Yang CH*, CJ Huang, CS Yang, YC Chu, AL Cheng, J Whang-Peng and PC Yang. Gefitinib
reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing
ATP-binding cassette family protein. Cancer Research. 2005 Aug 01;65(15):6943-9.
(*Corresponding author)
327. Yang CH, Chen MC, Cheng, AL, Hsu CH, Yeh KH, Yu YC, Whang-Peng J and Yang PC.
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose
epirubicin and paclitaxel as first-line treatment. Oncology. 2005 Jul;68(4-6):350-355.
328. Chu CY and Yang CH*. Docetaxel-induced recall dermatitis on previous laser treatment sites.
British Journal of Dermatology. 2005 Aug;153(2),441-3. (*Corresponding author)
329. SU WP, Yang CH *, Yu CJ, Shih JY, Hsu C and Yang PC. Gefitinib treatment for nonsmall cell
lung cancer – A study including patients with poor performance status. J Formos Med Assoc. 2005
Aug;104(8),557-562. (*Corresponding author)
330. Kuo SH, Yang CH*, Yu CJ, Hsu C, Cheng AL and Yang PC. Survival of stage IIIB/IV non-
small cell lung cancer patients who received chemotherapy but did not participate in clinical trials.
Lung Cancer. 2005 May;48,275-280. (*Corresponding author)
331. Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu HT, Li CC, Chen JS, Wu JS and
Cheng AL. Weekly gemcitabine plus 24-h infusion of high dose 5-fluorouracil/leucovorin for locally
advanced or metastatic carcinoma of the biliary tract. British Journal of Cancer. 2004
May;90,1715-1719.
332. Yang CH* Third-line chemotherapy for advanced nonsmall cell lung cancer – is there enough
evidence to support its use? J Chin Med Assoc. 2005 Apr;68(4),160-161. (editorial)
(*Corresponding author)
333. Yeh KH, Lu YS, Hsu CH, Lin JF, Chao HJ, Huang TC, Chung CY, Chang GS, Yang CH and
Cheng AL. Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus
leucovorin as first-line treatment for advanced breast cancer. British Journal of Cancer. 2005
Mar;92(6):1013-1018.
334. Lu YS, Hsu C, Li CC, Kuo SH, Yeh KJ, Yang CH, Hsu CH, Wu CY and Cheng AL. Phase II
study of combination doxorubicin, interferon-a and high dose tamoxifen treatment for advanced
hepatocellular carcinoma. Hepato-Gastroenterology. 2004 May:51(57),815-819.
335. Chie WC, Yang CH, Hsu C and Yang PC. Quality of life of lung cancer patients: validation of
the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Quality of Life Research.
2004 Feb:13(1),257-262.
336. Lin AM, Yang CH, Ueng YF, Luh TY, Lay YP, Ho LT. Differential effects of Carboxyfullerene
on MPP+/MPTP-induced neurotoxicity. Neurochem Int. 2004 Jan:44(2);99-105.
337. Ho CH, Yang CH and Chu CY. Vesicant-type reaction due to docetaxel extravasation. Acta
Derm Venereol. 2003: 83(6);467-468.
338. Lin MY, Fan SF, Yang DM, Hsu LL and Yang CH*. Zinc-induced apoptosis in substantia nigra
of rat brain neuroprotection by vitamin D3. Free Radical Biology and Medicine. 2003
Jun:34(11)1416-1425. (*Corresponding author)
339. Yang CH*, Chen YC and Kuo ML. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing
topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer
Research. 2003 May:23,2519-2524. (*Corresponding author)

340. Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF and Yeh KH. A phase II study of
weekly methotrexate, cisplatin and 24-hour infusion of high dose 5-fluorouracil and leucovorin in
patients with metastatic and recurrent esophageal cancer – improving toxicity profile by infusional
schedule a double biochemical modulation of 5-fluorouracil. Anticancer Research. 2002
Nov:22(6B),3621-3627.
341. Chu CY, Yang CH and Chiu HS. Fix erythrodysaesthesia plaque due to gemcitabine and
epirubicin treatment. Acta Derm Venereol. 2002 Feb: 82(2);147-148.
342. Yang CH, Tsai CM, Wang LS et al. Gemcitabine and cisplatin in a multimodality treatment for
locally advanced non-small cell lung cancer. British J Cancer. 2002 Jan: 86(2) ,190-195.
343. Chu CY, Yang CH and Chiu HS. Gemcitabine-induced acute lipodermatosclerosis-like reaction.
Acta Derm Venereol. 2001 Nov: 81(6);426-428.
344. Chu CY, Yang CH and Chiu HS. Inflammation of seborrheic keratoses due to docetaxel
treatment (letter). Acta Derm Venereol. 2001 Aug:81(4);316-317.
345. Yang CH*, Schneider E, Kuo ML, Volk EL, Rocchi E and Chen YC. BCRP/MXR/ABCP
expression in topotecan-resistant human breast carcinoma cells. Biochemical Pharmacology. 2000
Sep:60(6);831-837. (*Corresponding author)
346. Huang SY, Yang CH and Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic
leukemia: an useful salvage therapy. Leukemia and Lymphoma. 2000 Jul:38(3-4),283-293.
347. Rocchi E, Khodjakov A, Volk E, Yang CH, Litman T, Bates S, Schneider E. The product of the
ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane.
Biochemical and Biophysical Research Communications. 2000 Apr, 271(1), 42-46.
348. Chu CY, Yang CH, Yang CY, Hsiao GH and Chiu HS. Fixed erythrodysesthesia plaque due to
intravenous injection of docetaxel. British Journal of Dermatology. 2000 Apr:142,808-811.
349. Yang CH*, Kuo ML, Chen JC and Chen YC. Arsenic trioxide sensitivity is associated with low
level of glutathione in cancer cells. British Journal of Cancer. 1999 Nov:81(5),796-799.
(*Corresponding author)
350. Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF and Yang PC. High dose tamoxifen plus cisplatin
and etoposide in advanced inoperable non-small cell lung cancer. Cancer. 1999 Aug, 86:415-20.
351. Cheng AL, Yeh KH, Fine RL, Chuang SE, Yang CH, Wang LH and Chen DS. Biochemical
modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular
carcinoma. Hepato-Gastroenterology. 1998 Nov,45( 24):2005-10.
352. Kuo ML, Shen SC, Yang CH, Chuang SE, Cheng AL and Huang TS. Bcl-2 prevents
topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-
ribose)polymerase activity. Oncogene. 1998 Oct, 17:2225-2234.
353. Lin AM, Yang CH and Tsai CY. Striatal dopamine dynamic are altered following an intranigra
infusion of iron in adult rat. Free Radical Biol and Med. 1998 Apr, 24(6):988-993.
354. Hsu C, Yeh KH, Hong RL, Yang CH, Lin MT, Chen YC and Cheng AL. MVP salvage
chemotherapy for relapsed and refractory metastatic breast cancer. J Formos Med Assoc. 1997,
96(3):185-188.
355. Yang CH, and Cheng AL. “Polyprenoic acid to prevent second primary hepatomas”. New Engl
J.Med. 1996 Nov, 335(19):1460-1461. (Letter)
356. Yang CH, Horton JK, Cowan KH and Schneider E. Cross-resistance to camptothecin analogues
in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I
alterations. Cancer Research. 1995 Sep, 55: 4004-4009.
357. Yeh KH, Lin MT, Tang JL, Yang CH, Tsay W and Chen YC. Long-term disease-free survival
after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of
minimal residual disease in the transplant marrow by third-complementarity-detemining region-
specific probes. Br J Haematol. 1995 Apr, 89(4): 914-916.
358. Yeh KH, Hsieh HC, Tang JL, Lin MT, Yang CH and Chen YC. Severe isolated acute hepatic
graft-versus-host disease with vanishing bile duct syndrome. Bone Marrow Transplant. 1994 Aug,
14(2):319-321.

359. Schneider E, Horton JK, Yang CH, Nakagawa M and Cowan KH. Multidrug Resistance-
associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a
Human Breast Carcinoma MCF-7 Cell Line selected for Etoposide Resistance. Cancer Research.
1994 Jan, 54: 152-158.
360. Hong RL, Shen SW, Lin MT, Tien HF, Yang CH and Chen YC. Lymphoblast Colony Culture
Assay in Acute Lymphoblastic Leukemia: A Quantitative Approach. Leukemia Research. 1993
May, 17(5): 463-70.
361. Yang CH, Lin MT, Tsay W, Lin LT, Wang CH and Chen YC. Autologous Bone Marrow
Transplantation for Plasma Cell Leukemia: Report of a Case. Transplant Proceedings. 1992 Aug,
4:1531-1532.